Narrow search
Showing 1 - 10 of 152
Cover Image
The effects of drug market regulation on pharmaceutical prices in Europe : overview and evidence from the market of ACE inhibitors
Schulenburg, Fritz von der; Vandoros, Sotiris; Kanavos, … - In: Health economics review 1 (2011) 18, pp. 1-8
in reducing pharmaceuticals prices. Results are not as strong for demand side measures. Profit controls and the use of …
Persistent link: https://www.econbiz.de/10009503923
Cover Image
The impact of reference pricing and extension of generic substitution on the daily cost of antipsychotic medication in Finland
Koskinen, Hanna; Ahola, Elina; Saastamoinen, Leena K.; … - In: Health economics review 4 (2014) 9, pp. 1-10
Objective: To assess the impact of reference pricing and extension of generic substitution on the daily cost of antipsychotic drugs in Finland during the first year after its launch. Furthermore, the additional impact of reference pricing on prior implemented generic substitution is assessed....
Persistent link: https://www.econbiz.de/10010528479
Cover Image
Will vaccination against rotavirus infection with RIX4414 be cost-saving in Germany?
Knoll, Stefanie; Mair, Christoph; Benter, Ursula; Vouk, … - In: Health economics review 3 (2013) 27, pp. 1-11
Background: Rotavirus gastroenteritis (RVGE) is a frequent disease in young children. The recommended German paediatric immunisation schedule does not currently include rotavirus vaccination. A lack of economic data on the impact of routine vaccination is stated as one of the reasons. As a...
Persistent link: https://www.econbiz.de/10010242226
Cover Image
The cost-effectiveness of celecoxib versus non-steroidal anti-inflammatory drugs plus proton-pump inhibitors in the treatment of osteoarthritis in Saudi Arabia
Nasef, Sherif A.; Shaaban, A. Aziz; Mould-Quevedo, Joaquin - In: Health economics review 5 (2015) 13, pp. 1-8
Background: Cyclooxygenase (COX)-2 inhibitors including celecoxib are as effective as non-selective non-steroidal anti-inflammatory drugs (ns-NSAIDs) in the treatment of osteoarthritis (OA) and have less gastrointestinal toxicity. Although they are associated with higher treatment costs, COX-2...
Persistent link: https://www.econbiz.de/10011471466
Cover Image
Economic impact of homeopathic practice in general medicine in France
Colas, Aurélie; Danno, Karine; Tabar, Cynthia; Ehreth, … - In: Health economics review 5 (2015) 18, pp. 1-9
Health authorities are constantly searching for new ways to stabilise health expenditures. To explore this issue, we compared the costs generated by different types of medical practice in French general medicine: i.e. conventional (CM-GP), homeopathic (Ho-GP), or mixed (Mx-GP). Data from a...
Persistent link: https://www.econbiz.de/10011471577
Cover Image
Cardiovascular drug shortages in Lebanon : a broken heart
Khattar, Georges; Hallit, Jennifer; El Chamieh, Carolla; … - In: Health economics review 12 (2022) 1, pp. 1-2
For nearly 3 years now, Lebanon has been assailed by compounded crises. With the economic instability, the coronavirus pandemic, and the explosion of the Beirut Port on August 4, 2020; the fragile Lebanese healthcare system has found itself at massive risk of a catastrophic public health crisis...
Persistent link: https://www.econbiz.de/10013198765
Cover Image
The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany
Dintsios, C. M.; Beinhauer, I. - In: Health economics review 10 (2020) 7, pp. 1-25
Background: We analysed the impact of clinical study design for oncological pharmaceuticals on the subsequent price … Health Insurance Funds. The analysis was conducted for all oncology pharmaceuticals that underwent the early benefit …. Further analyses should be performed when more oncology pharmaceuticals have passed the early benefit assessment. …
Persistent link: https://www.econbiz.de/10012291135
Cover Image
The impact of reimbursement negotiations on cost and availability of new pharmaceuticals: evidence from an online experiment
Wettstein, Dominik J.; Boes, Stefan - In: Health economics review 10 (2020) 13, pp. 1-15
Background: The necessity to measure and reward "value for money" of new pharmaceuticals has become central in health … study assesses the impact of a negotiation situation for lifeextending pharmaceuticals on societal outcomes. Of interest …
Persistent link: https://www.econbiz.de/10012291180
Cover Image
Implementing personalized medicine with asymmetric information on prevalence rates
Antoñanzas Villar, Fernando; Juárez-Castelló, Carmelo A. - In: Health economics review 6 (2016) 35, pp. 1-8
Although personalized medicine is becoming the new paradigm to manage some diseases, the economics of personalized medicine have only focused on assessing the efficiency of specific treatments, lacking a theoretical framework analyzing the interactions between pharmaceutical firms and healthcare...
Persistent link: https://www.econbiz.de/10011586604
Cover Image
Pre-approval incentives to promote adoption of personalized medicine : a theoretical approach
Antoñanzas Villar, Fernando; Juárez-Castelló, C. A.; … - In: Health economics review 9 (2019) 28, pp. 1-10
Background: Currently, personalised medicine is becoming more frequently used and many drug companies are including this strategy to gain market access for very specialized therapies. In this article, in order to understand the relationships between the health authority and the drug company when...
Persistent link: https://www.econbiz.de/10012162381